This site is intended for health professionals only

NicOx to hold extraordinary shareholder meeting


NicOx S.A. (NYSE Euronext Paris: COX) has convened an extraordinary shareholder meeting on second call on the same agenda on Friday July 27, 2012 at 12:30 pm CET at the Mercure hotel – rue Albert Caquot – 06560 Sophia Antipolis – France.

The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce, including a proxy voting form, are sent to shareholders upon written request. These documents are available to shareholders at the headquarters and on the website of the Company (

For questions on the voting procedures, a telephone line is made available to shareholders. The dial number is +33 (0)4 97 24 54 44. Shareholders may also contact the Investor Relations team by email at [email protected].

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is building an international late-stage development and commercial Ophthalmology Company based around therapeutics, diagnostics and devices.

┬áNicOx is also developing an internal portfolio of New Molecular Entities (NMEs) through the application of its proprietary nitric oxide-donating R&D platform. The Company’s pipeline includes several nitric oxide-donating NMEs for the potential treatment of ophthalmological, inflammatory and cardio-metabolic diseases, which are in development internally and with partners, who include Bausch + Lomb, Merck (known as MSD outside the United States and Canada) and Ferrer.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: Small Caps).


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine